Life sciences

Straightforward, business-friendly advice from lawyers who understand the unique challenges and opportunities presented by the life sciences sector.  We enjoy spending time getting to know our clients and working alongside them for the long term. Visit our life sciences hub
  • Profile
  • Key contacts

We work with a wide range of clients from the life sciences sector including:

  • pharmaceutical companies
  • biotechnology companies
  • medical device and diagnostic companies
  • manufacturers, distributors and logistics companies
  • investors
  • banks and financial institutions. 

"Very professional, pragmatic, business-minded, knowledgeable team that advise as if they were part of the team."

The Legal 500 UK 2022

Lawyer

Dan Holland Partner

T:  +44 20 7809 2108
M:  +44 7841 923 656 Email Dan | Vcard Office:  London

Lawyer

Rob Jacob Partner

T:  +44 20 7809 2072
M:  +44 7825 601 925 Email Rob | Vcard Office:  London

Lawyer

Naomi Leach Partner

T:  +44 20 7809 2960
M:  +44 7769 143 367 Email Naomi | Vcard Office:  London

Lawyer

Tom Page Partner

T:  +44 20 7809 2021
M:  +44 7813 600 516 Email Tom | Vcard Office:  London

Lawyer

Alexandra Pygall Partner

T:  +44 20 7809 2137
M:  +44 7881 314 566 Email Alexandra | Vcard Office:  London

Lawyer

Kristian Shearsby Partner

T:  +44 20 7809 2813
M:  +44 7880 488 532 Email Kristian | Vcard Office:  London

Latest news & insights

22 Sep 2022

From Insights

Court orders damages and civil penalties for unlawful NHS procurement

This recent High Court judgement will be of interest to companies in the life sciences sector that supply products and service into the UK NHS.

More

29 Jul 2022

From Insights

UK government blocks IP licence over national security concerns

On 20 July 2022, the UK's Secretary of State for Business, Energy and Industrial Strategy announced that a final order had been issued, blocking the licensing of intel..

More

13 Jul 2022

From News

Stephenson Harwood advises Oxford Biomedica on new AstraZeneca agreement

Law firm Stephenson Harwood LLP has advised Oxford Biomedica, the gene and cell therapy company, on its new three year Master Services & Development Agreement with Ast..

More

22 Jun 2022

From Insights

The Public Procurement Bill 2022 has a second reading in the House of Lords

Since Brexit, and the subsequent pandemic when the direct award of PPE contracts was in the spotlight, the question of how public procurement will be regulated in the ..

More

07 Apr 2022

From Insights

F is for foreign investment: UK’s new foreign investment screening regime – What you need to know?

The UK’s National Security & Investment Act 2021, which entered into force on 4 January 2022, has created for the first time a standalone foreign direct investment reg..

More

18 Mar 2022

From Insights

E is for equity investment

2020 and 2021 were both bumper years for venture funding but the spotlight was firmly on the life sciences sector. In 2021, £4.5 billion was raised by UK biotech and l..

More

14 Feb 2022

From Insights

D is for data opt-out

The national data opt-out ("NDO") was introduced on 25 May 2018 enabling patients to opt out from the use of their personal data for research or planning purposes.

More

13 Dec 2021

From Insights

Life sciences podcast

The Stephenson Harwood life sciences podcast provides an overview of key legal developments relating to the sector.

More

07 Dec 2021

From Insights

C is for collaboration arrangements

​This month we are exploring, at a high-level, the use of collaboration agreements in the life sciences sector, and some of the issues to consider.

More

01 Nov 2021

From Insights

Life sciences - Still in the antitrust spotlight

Over the last few years, the UK and EU competition authorities have continued to closely scrutinise the life sciences sector

More

11 Oct 2021

From Insights

UK Public Procurement Reform – What's the latest?

Earlier this year, we wrote a series of articles setting out our thoughts on the UK Government's bold plans for the reform of public procurement regulation set out in ..

More

20 Aug 2021

From Insights

D-day announced – UK's new National Security and Investment Act regime to begin on 4 January 2022

On 20 July 2021, BEIS announced that the new screening regime under the NSIA would officially commence on 4 January 2022. Alongside this announcement, BEIS also publis..

More

29 Jul 2021

From Insights

B is for Biologics License Application

A BLA is a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce in the US. By way of background, the US has a ..

More

16 Jun 2021

From Insights

A for Artificial Intelligence

The use of AI within the life sciences industry is a hot topic with many excited about its potential uses, but how will its use be regulated?

More

08 Jun 2021

From News

Stephenson Harwood advises Apposite Capital on Emblation investment

Law firm Stephenson Harwood LLP has advised healthcare investor Apposite Capital on its investment in medical device company, Emblation.

More

16 Mar 2021

From Insights

UK Government provides more clarity on the scope of the National Security and Investment Bill (“NSIB”)

We are pleased to share with you our briefing on the UK Government’s response to a public consultation concerning the 17 key sectors subject to the mandatory notificat..

More

print-footer
logo
© Stephenson Harwood LLP 2016. Any reference to Stephenson Harwood in this document means Stephenson Harwood LLP and/or its affiliated undertakings. Any reference to a partner is used to refer to a member of Stephenson Harwood LLP.